Overexpression of thioredoxin has been demonstrated to have a momentous functional implication in mitigating cardiomyocyte dysfunction from DM-induced oxidative stress, which is expected to become a key target for the drug-based treatment of DCM (84, 85). The gene discussed is TXN; the disease is familial dilated cardiomyopathy.